Eli Lilly

AITech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems
By Jake AngeloMarch 2, 2026

By Jeffrey Sonnenfeld, Stephen Henriques, Ferron Chen, Asuka Koda and Vanessa McLennanFebruary 11, 2026

NewslettersWhy big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
By John KellNovember 19, 2025

HealthTrump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic
By Nick LichtenbergNovember 6, 2025

HealthAdult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By Matty Merritt and Morning BrewOctober 31, 2025

By Eric Pfanner and BloombergMay 16, 2025

By Jonel Aleccia and The Associated PressMay 12, 2025

PoliticsViagra and Mounjaro panic-buying could be behind a 200% export surge from Ireland to the U.S.
By Ryan HoggApril 30, 2025

By Marthe Fourcade and BloombergApril 22, 2025

By Paula Doenecke, Naomi Kresge and BloombergMarch 12, 2025

CommentaryThe crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By Wendy BarnesMarch 4, 2025

By Madison Muller and BloombergFebruary 26, 2025

By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
Most Popular




